Larimar Therapeutics (LRMR) risk factors, FY2025 10-K

Risks Related to Our Financial Position and Need for Capital

1. 01We have incurred significant losses since our inception and anticipate that we will incur continued losses for the foreseeable future20% rewritten
2. 02experience any delays or encounter issues with any of the above
3. 03To date, we have not generated any commercial revenue. Our ability to generate revenue and become profitable depends upon our ability to obtain regulatory approval for, and to successfully commercialize, nomlabofusp or other product candidates that we may develop, in-license or acquire in the future
4. 04set a commercially viable price for any products for which we may receive approval
5. 05As of December 31, 2025, our existing cash, cash equivalents and marketable securities were $136.9 million. Together with the $107.6 million in net proceeds from our recently completed February 2026 public offering, we expect this will fund operations into the second quarter of 2027New
6. 06Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies, nomlabofusp or other product candidates that we may develop, in-license or acquire in the future
7. 07Our ability to use our NOLs and certain other tax attributes may be limited73% rewritten
8. 08Changes in tax laws and regulations may have a material adverse effect on our business, financial condition and results of operations

Risks Related to Our Product Development and Regulatory Approvals

1. 09Our success is currently dependent upon the success of our lead product candidate, nomlabofusp. We cannot be certain that we will ultimately be successful with our clinical development or that we will ever be able to obtain regulatory approval for nomlabofusp39% rewritten
2. 10competing with other therapies
3. 11Clinical development is a lengthy and expensive process with an uncertain outcome, and the results of non-clinical studies, toxicology studies or clinical trials may not be predictive of future non-clinical studies, toxicology studies or clinical trial results
4. 12Failures or delays in the completion of our clinical trials could result in increased costs and could delay, prevent or limit our ability to generate revenue and continue our business23% rewritten
5. 13We may not be successful in our efforts to identify, discover or acquire additional product candidates
6. 14We have no marketed proprietary products and have not yet advanced a product candidate beyond Phase 2 clinical trials, which makes it difficult to assess our ability to develop nomlabofusp or any future product candidates and commercialize any resulting products independently
7. 15manage our spending as costs and expenses increase due to clinical trials, regulatory approvals and commercialization activities
8. 16We cannot be certain that we will be able to successfully complete clinical trials for nomlabofusp or any other product candidates
9. 17FA has no FDA-approved therapies that address frataxin deficiency, which is the underlying cause of the disease, and clinical endpoints required to obtain approval are not well defined73% rewritten
10. 18nomlabofusp elsewhere or result in regulatory authorities restricting our ability to develop or commercialize nomlabofusp, if approvedNew
11. 19our reputation may suffer and physicians or patients might be less likely to use our product or may refer patients to products produced by our competitors
12. 20Our approach to discover and develop fusion proteins for delivering proteins is novel and may never lead to marketable products
13. 21Nomlabofusp uses a novel and unproven approach and mechanism to treat FA and therefore its efficacy and safety are difficult to predict, and there is no guarantee that nomlabofusp will be approved by the FDA, the EMA, or any other regulatory authorities
14. 22Protein replacement therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the development or commercialization of our protein replacement therapy platform or product candidates or otherwise harm our business
15. 23The FDA's Fast track Designation and its Breakthrough Therapy Designation or any future expedited program designations may not lead to a faster development, regulatory review or approval process and it does not increase the likelihood that any of our product candidates will receive marketing approval27% rewritten
16. 24we disseminate false or misleading promotional materials relating to the relevant product candidate63% rewritten
17. 25planned BLA, which will materially adversely affect our business and could potentially cause us to ceaseNew
18. 26If we fail to maintain orphan drug designation or other regulatory exclusivity for nomlabofusp or obtain such exclusivity for any of our other product candidates in the future, our competitive position would be harmed21% rewritten
19. 27Although we have obtained rare pediatric disease designation for nomlabofusp, we may not be eligible to receive a priority review voucher in the event the FDA determines we no longer meet the criteria for designation, revokes the designation or FDA approval does not occur prior to September 30, 202643% rewritten
20. 28If we fail to maintain PRIME designation in the European Union for nomlabofusp, our competitive position could be harmed52% rewritten
21. 29relevant model provide early evidence of promising activity to establish proof of principle, and first-in-human studies indicate adequate exposure for the desired pharmacotherapeutic effects and tolerabilityNew
22. 30For SMEs who enter the scheme based on data showing proof of principle, the appointment of the rapporteur occurs once they have generated data confirming eligibility at proof of concept stage. They are required to submit relevant data and justification as the product development reaches this stage
23. 31Delays, failure or unexpected costs in obtaining, the regulatory approval necessary to bring our product candidates to market could have a material adverse effect on our business, results of operations, financial condition and prospects
24. 32Even after successful completion of clinical trials, there is a risk that the FDA or other regulatory agencies may request further information from us, disagree with our findings or otherwise undertake a lengthy review of our submission
25. 33the FDA or the EMA may change their approval policies or adopt new regulations rendering our clinical data insufficient for approval
26. 34We are subject to healthcare laws and regulations, and health information privacy and security laws, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings
27. 35Healthcare legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates
28. 36Even if approved, reimbursement policies could limit our ability to sell product candidates that we elect to sell on our own
29. 37Even if we obtain marketing approval for a product candidate, our product candidates will remain subject to regulatory oversight
30. 38refuse to allow us to enter into supply contracts, including government contracts
31. 39Even if we receive marketing approval for nomlabofusp in the United States, we may never receive regulatory approval to market nomlabofusp outside of the United States
32. 40Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties
33. 41the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute
34. 42If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell nomlabofusp, if approved, we may not be able to generate any revenue
35. 43Even if we receive marketing approval for nomlabofusp, we may not achieve broad market acceptance, which would limit the revenue that we generate from our sales
36. 44the likelihood that the FDA may require development of a REMS, as a condition of approval or post-approval or may not agree with our proposed REMS or may impose additional requirements that limit the promotion, advertising, distribution or sales of our product candidates
37. 45The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found to have improperly promoted off-label uses, we may become subject to significant liability38% rewritten
38. 46Additional competing technologies could emerge, adversely affecting our opportunity to generate revenue from the sale of nomlabofusp, if approved
39. 47We may face competition from biosimilars and may face increasing competition over time

Risks Related to Our Business

1. 48If we are unable to manage expected growth in the scale and complexity of our operations, including attracting and hiring additional qualified management, our performance may suffer72% rewritten
2. 49We may acquire businesses or products, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions or alliances
3. 50We may seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans or expand our internal efforts and growth
4. 51We face risks related to health epidemics, and/or other outbreaks of communicable diseases, which could significantly disrupt our operations and may materially and adversely affect our business and financial conditions56% rewritten
5. 52several other states, as well as at the federal and local levels, and we expect more jurisdictions to pass similar laws in the futureNew
6. 53impact assessments. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer lawsNew
7. 54Insurance policies, including a specific policy related to cybersecurity losses, may be insufficient, with potential availability issues in the future, high deductibles, and limitations in coverage, posing challenges in mitigating losses from disruptions, failures, or security breaches
8. 55In the ordinary course of our business, we, or the third parties upon which we rely, process proprietary, confidential, and sensitive data, including personal data (such as health-related data), intellectual property, and trade secrets70% rewritten
9. 56the third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our productsNew
10. 57Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations
11. 58We face risks related to information technology regulatory and compliance requirements
12. 59We face the risk of shadow IT and unapproved software use by employees
13. 60We face potential product liability exposure, and, if claims are brought against us, we may incur substantial liability
14. 61the inability to successfully commercialize nomlabofusp or other potential product candidates, if approved
15. 62Artificial intelligence presents risks and challenges that can impact our business, including by posing security risks to our confidential information, proprietary information and personal dataNew

Risks Related to Our Reliance on Third Parties

1. 63We have limited experience in conducting or supervising clinical trials and must outsource all clinical trials. As a result, many important aspects of our drug development programs are outside of our direct control
2. 64We rely on supply and manufacturing partners for drug supplies for our research and development, non-clinical activities, and clinical activities, and plan to do the same for any commercial supplies of our product candidates50% rewritten
3. 65guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budgetNew
4. 66We and our contract manufacturers are subject to significant regulation with respect to manufacturing our products. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity
5. 67Changes in methods of product candidate manufacturing may result in additional costs and/or delays
6. 68Our contract manufacturers may be unable to successfully scale up manufacturing of our product candidate in sufficient quality or quantity in a timely manner, if at all, which may impair the clinical advancement and commercialization of our product candidateNew
7. 69We enter into various contracts in the normal course of our business in which we indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could materially increase our costs and potential liability
8. 70To the extent we are able to enter into collaborative arrangements or strategic alliances, we may be exposed to risks related to those collaborations and alliances

Risks Related to Our Intellectual Property Rights

1. 71that our commercial activities or products will not infringe upon the patents of others
2. 72Our key patents relating to nomlabofusp, which we license, will expire in 2040 and we will lose our ability to rely upon these patents to prevent competing products from entering the market, which may impair our ability to generate revenue31% rewritten
3. 73Our success will depend in part on our ability to operate without infringing the intellectual property and proprietary rights of third parties. We cannot ensure that our business, products and methods do not or will not infringe the patents or other intellectual property rights of third parties
4. 74In addition, if any such claim were successfully asserted against us and we could not obtain such a license, we may be forced to stop or delay developing, manufacturing, selling or otherwise commercializing nomlabofusp
5. 75We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
6. 76Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
7. 77We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful
8. 78We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States, which could adversely affect our business, financial condition and results of operations
9. 79Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court
10. 80We do not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection
11. 81We have an exclusive license with IU, pursuant to which we exclusively license certain patent rights relating to nomlabofusp and its use for the treatment of mitochondrial diseases, on a worldwide basis. We have a past license with WFUHS in which we exclusively licensed certain patent rights for patents now expiredNew
12. 82the priority of invention of patented technology
13. 83We have not yet registered trademarks for a commercial trade name for nomlabofusp or other potential product candidates and failure to secure such registrations could adversely affect our business, financial condition and results of operations
14. 84Any trademarks we have obtained or may obtain may be infringed or successfully challenged, resulting in harm to our business
15. 85If we do not obtain additional protection under the Hatch-Waxman Amendments and similar foreign legislation by extending the patent terms and obtaining data exclusivity for nomlabofusp, our business may be materially harmed
16. 86Our proprietary rights may not adequately protect our technologies, which may adversely affect our position in the market, business, financial condition and results of operations
17. 87Changes in patent law in the U.S. and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
18. 88We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our employees’ former employers

Risks Related to Our Common Stock

1. 89Our stock price could be highly volatile, and purchasers of our common stock could incur substantial losses
2. 90Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies or the biotechnology sector. These broad market fluctuations may also adversely affect the trading price of our common stock
3. 91We must maintain effective internal controls over financial reporting, and if we are unable to do so, the accuracy and timeliness of our financial reporting may be adversely affected, which could have a material adverse effect on our business and stock price
4. 92Ownership of our common stock is highly concentrated, and it may prevent other stockholders from influencing significant corporate decisions35% rewritten
5. 93We are a smaller reporting company. We cannot be certain whether the reduced disclosure requirements applicable to smaller reporting companies will make our common shares less attractive to investors or otherwise limit our ability to raise additional funds
6. 94Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management
7. 95We do not anticipate that we will pay any cash dividends in the foreseeable future
8. 96Our failure to meet the continued listing requirements of The Nasdaq Stock Market LLC could result in a delisting of our Common Stock
9. 97Financial reporting obligations of being a public company in the United States are expensive and time-consuming, and our management will be required to devote substantial time to new compliance matters
10. 98Our employees may engage in misconduct or other improper activities, including violating applicable regulatory standards and requirements or engaging in insider trading, which could significantly impact our business
11. 99Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations
12. 100Adverse developments affecting the financial services industry, including events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our business, financial condition or results of operations